GPC3 antibody patent - methods of use for cancer treatment
Summary
The USPTO granted patent US12595314B2 to R.P. Scherer Technologies, LLC for antibodies specific to glypican-3 (GPC3). The patent covers 37 claims including the antibody compositions, nucleic acids encoding the antibodies, methods of manufacturing, and therapeutic uses for treating cell proliferative disorders by enhancing immune responses such as T cell responses to cancer cells.
What changed
USPTO issued patent grant US12595314B2 to R.P. Scherer Technologies covering antibodies targeting glypican-3 (GPC3), a proteoglycan overexpressed in liver cancer and other malignancies. The patent includes claims to the antibody compositions, encoding nucleic acids, production methods, and methods of treatment involving immune response enhancement against GPC3-expressing cells.
Pharmaceutical and biotechnology companies developing GPC3-targeted cancer therapeutics should consider this patent when designing R&D programs or seeking licensing arrangements. Competitors may need to design around these claims or seek licenses to avoid infringement in this oncological antibody space.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Antibody specific for GPC3 and methods of use thereof
Grant US12595314B2 Kind: B2 Apr 07, 2026
Assignee
R.P. Scherer Technologies, LLC
Inventors
David Rabuka, Penelope M. Drake, Yun Cheol Kim, Robyn M. Barfield, Maxine Bauzon
Abstract
The present disclosure provides antibodies specific for glypican-3 (GPC3). Nucleic acids that encode one or both of the variable chain polypeptides of an antibody of the present disclosure are also provided, as are cells that include such nucleic acids. Also provided are compositions that include the antibodies of the present disclosure, including in some instances, pharmaceutical compositions. Methods of making and using the antibodies of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having a cell proliferative disorder a therapeutically effective amount of an antibody of the present disclosure, where the antibody is administered to the individual to enhance an immune response, e.g., a T cell response, to abnormally proliferating cells of the cell proliferative disorder. The antibodies are useful in various diagnostic, and monitoring applications, which are also provided.
CPC Classifications
C07K 16/303 C07K 2317/33 C07K 2317/565 C07K 16/18 C07K 16/28 C07K 2317/24 C07K 2317/31 C07K 2317/55 C07K 2317/62 C07K 2317/622 A61P 35/00 A61K 2039/505
Filing Date
2020-07-31
Application No.
17629297
Claims
37
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.